Roche Acquires THP to Expand its Therapeutic Antibody Research

Roche today announced that it has acquired Therapeutic Human Polyclonals, Inc. (THP) a privately-owned biotechnology company based in California and Germany. With its focus on innovative antibody research, THP will be a valuable addition to Roche’s research organization.

“We are delighted about this acquisition as it builds on our strength in therapeutic antibodies,” said Jonathan Knowles, Head of Global Research. “THP and its employees will add cutting-edge capabilities and represent an excellent strategic fit with our own R&D organization. We look forward to welcoming the new members to Roche.”

Roche paid $56.5 million (US) in cash to acquire 100% ownership of THP and plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research in Penzberg, Germany.

Modern medical biotechnology uses a wide range of methods to diagnose and treat diseases – from the production of natural products and gene therapy to therapeutic proteins and antibodies. As a company heavily invested in biotechnology and focused on providing added value to patients and healthcare providers, the development of therapeutic proteins and antibodies remains a major emphasis at Roche.